Minkyung Oh

Inje University Paik Hospital, Sŏul, Seoul, South Korea

Are you Minkyung Oh?

Claim your profile

Publications (23)57.53 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Aim: The primary objective of this study was to evaluate pharmacokinetic and pharmacodynamic interactions between clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes. Methods: In a randomized, 3-way crossover study, 27 healthy subjects were administered clopidogrel (300 mg), cilostazol (100 mg), or clopidogrel + cilostazol orally. Plasma concentrations of clopidogrel, cilostazol and their active metabolites (clopidogrel thiol metabolite, 3,4-dehydrocilostazol and 4'-trans-hydroxycilostazol), and ADP-induced platelet aggregation were measured for pharmacokinetic and pharmacodynamic assessment. Results: The area under the plasma concentration-time curve (AUC) of clopidogrel active thiol metabolite was highest in CYP2C19 extensive metabolizer (EM) and lowest in poor metabolizers (PM). Cilostazol decreased thiol metabolite AUC 29% in CYP3A5*1/*3 (Geometric mean ratio (GMR), 0.71; 90% CI, 0.58-0.86; p = 0.020) but not in CYP3A5*3/*3 (GMR, 0.93; 90% CI, 0.80-1.10; p = 0.446). Known CYP2C19 or CYP3A5 genotype effects on cilostazol and its metabolites exposure were observed, but there was no significant difference in the AUC of cilostazol and 3,4-dehydro-cilostazol between cilostazol and clopidogrel + cilostazol. The inhibition of platelet aggregation from 4 hrs to 24 hrs (IPA4-24 ) following administration of clopidogrel alone was highest in CYP2C19 EM genotype, and lowest in CYP2C19 PM genotype (59.05 ± 18.95 vs. 36.74 ± 13.26, P = 0.023). However, IPA of CYP2C19 PM following co-administration of clopidogrel and cilostazol was comparable to that of CYP2C19 EM and IM only in CYP3A5*3/*3. Conclusions: Additive antiplatelet effect of cilostazol to clopidogrel is maximized in subjects with both CYP2C19PM and CYP3A5*3/*3 because of lack of change of clopidogrel thiol metabolite exposure in CYP3A5*3/*3 as well as the highest cilostazol IPA in CYP2C19 PM or CYP3A5*3/*3. This article is protected by copyright. All rights reserved.
    No preview · Article · Oct 2015 · British Journal of Clinical Pharmacology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: This study aimed to assess solid thyroid nodule (STN) cases with discordant sonographic and cytological diagnoses and to compare the diagnostic indices of these modalities. Methods: From January 2013 to December 2013, a single radiologist performed consecutive thyroid ultrasonography (US) and US-guided fine-needle aspiration (US-FNA) to diagnose 347 STNs in 347 patients. Each STN was classified into 1 of 5 categories according to the US diagnosis before US-FNA: "benign," "probably benign," "indeterminate," "suspicious for malignancy," or "malignant." We assessed cases where the sonographic and cytological STN diagnoses were discordant, using the final diagnosis as the reference standard. Results: Of the 347 STNs, 279 (80.4%) had a final diagnosis confirmed. The "benign," "probably benign," and "malignant" US categories showed high concordance with the cytological diagnoses, whereas the "suspicious for malignancy" US category revealed only a 62.2% concordance rate. The prevalence of indeterminate cytology was higher in the "indeterminate" and "suspicious for malignancy" US categories than other US categories. STNs with indeterminate cytology showed a higher malignancy rate in the malignant US categories. When STNs classified into indeterminate categories from the sonographic (n = 49) and cytological (n = 18) diagnoses were excluded, the sensitivity, specificity, and accuracy of the sonographic and cytological diagnoses were 95.5 and 98.8%, 92.1 and 100%, and 93.0 and 99.6%, respectively. Conclusion: The "suspicious for malignancy" US category showed higher discordance with cytological diagnoses than other US categories, and the diagnostic value of US was lower than that of cytology. Diagn. Cytopathol. 2015;00:000-000. © 2015 Wiley Periodicals, Inc.
    No preview · Article · Sep 2015 · Diagnostic Cytopathology
  • Source
    MinKyung Oh · Jaeseung Yoon · Doo-Yeoun Cho
    [Show abstract] [Hide abstract]
    ABSTRACT: Background and objectives: A new biosimilar human recombinant epoetin alfa product (PDA10) has been developed by PanGen Biotech Inc., Korea. This study was planned to demonstrate the pharmacokinetic and pharmacodynamic comparability of PDA10 to an existing epoetin alfa (Eprex) after a single intravenous administration to healthy adult male volunteers. Methods: A randomized, double-blinded, single-dose, crossover study was conducted in 30 subjects. The subjects were assigned randomly to one of two sequence groups, and single doses of 100 IU/kg PDA10 or Eprex were administered intravenously on each of 2 treatment days separated by a 4-week washout period. Plasma erythropoietin concentrations were measured using an enzyme-linked immunosorbent assay and the pharmacokinetic parameters of the two treatments were compared. The time course and area under the effect curve (AUEC) of absolute reticulocyte counts were used as surrogate parameters for the pharmacodynamic evaluation. Adverse events (AEs) were recorded. Results: A total of 30 subjects were enrolled, and 27 completed the study. The geometric mean ratios (PDA10/Eprex) of erythropoietin for maximum plasma concentration (C max) and area under the plasma concentration-time curve to the last measurable concentration (AUC0-last) after intravenous administration of 100 IU/kg were 1.00 (90 % confidence interval [CI] 0.96-1.05) and 0.96 (90 % CI 0.93-1.00). The absolute reticulocyte counts of PDA10 and Eprex were similar, as determined from the maximum reticulocyte count and AUEC0-last values. Treatment-emergent AEs were mild and occurred in seven subjects. Conclusion: PDA10 and Eprex met the regulatory criteria for bioequivalence with respect to their pharmacokinetic profiles and pharmacodynamic actions.
    Full-text · Article · Sep 2015 · Clinical Drug Investigation
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to assess the accuracy of ultrasound (US) and individual US features in the diagnosis of nodal metastasis in patients with papillary thyroid carcinoma (PTC) with respect to nodal compartment. US diagnoses and individual US features of nodal metastases with respect to nodal compartment were investigated in 184 consecutive PTC patients who underwent pre-operative US. Histopathologic results were used as a reference standard. One hundred thirty-six of 368 (37.0%) central compartments contained one or more metastatic nodes, whereas 44 of 48 (91.7%) lateral compartments had one or more metastatic nodes. The malignancy rates of suspicious US diagnoses in the central and lateral compartments were 66.3% (53/80) and 93.3% (42/45), respectively. The central and lateral compartments differed significantly in nodal composition, echogenicity, calcification, shape, hilar echogenicity and vascularity. The accuracy of US in the diagnosis of nodal metastases from PTC was lower in the central compartment than in the lateral compartment. Copyright © 2015 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.
    No preview · Article · Feb 2015 · Ultrasound in Medicine & Biology
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to compare the pharmacokinetic characteristics of metformin between a fixed-dose combination (FDC) of voglibose/metformin and coadministered individual voglibose and metformin tablets in healthy Korean volunteers under fasting conditions. A randomized, open-label, single-dose, two-treatment, two-way crossover study with a 7-day wash-out period was conducted. Plasma samples were collected for up to 24 hours and were analyzed for metformin using a validated liquid chromatography tandem mass-spectrometry (LC/MS). A noncompartmental method was used to calculate the pharmacokinetic parameters. Vital signs and adverse events were monitored, and physical examinations and laboratory tests were conducted to evaluate safety. In total, 28 subjects completed the study. The geometric mean ratio (GMR) and the 90% confidence interval (CIs) of Cmax and AUC0-t of metformin were 102.4 (94.5 - 111.0) and 107.1 (100.1 - 114.7), respectively. In total, 7 adverse drug reactions occurred in 4 subjects during the study; of these, 3 cases were from 3 subjects in the test treatment group, and 4 cases were from 3 subjects in the reference treatment group. All adverse drug reactions had been reported previously, and all subjects recovered fully without any sequelae. In conclusion, the pharmacokinetic profiles of metformin in two different study treatments, a voglibose/metformin FDC vs. the coadministration of the individual formulations, met the regulatory criteria for bioequivalence in healthy Korean subjects under fasting conditions. There was no significant difference in safety profiles between the two treatments.
    Preview · Article · Dec 2014 · International journal of clinical pharmacology and therapeutics
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Gastrin increases the growth and neogenesis of the islets of Langerhans. Oral proton pump inhibitors (PPIs) increase the circulating gastrin level in animals and humans, but the therapeutic benefit of PPIs for diabetes mellitus has not been resolved. We examined whether treatment with a PPI for ≥2 months affected the glycated hemoglobin (A1C) level in patients with type 2 diabetes. Methods: The electronic medical records of patients treated at the Busan Paik Hospital in South Korea were examined. The primary outcome measure was the change in A1C before and after PPI treatment for ≥2 months. We also tested if the primary outcome measure was affected by sex, age, duration of diabetes, body mass index, PPI molecule, duration of treatment with PPI or concurrent therapy with other antidiabetes agents. Results: In total, 43 patients (17 men and 26 women) were studied (mean age 63.8 years). Patients were treated with a PPI for a mean of 180 days. The A1C levels before and after treatment were not significantly different (6.86%±1.10% and 6.77%±1.07%, respectively; p=0.406). Metformin monotherapy did not lower A1C levels as compared with a combination therapy including metformin and antidiabetes medication not including metformin. Conclusions: Proton pump inhibitor treatment of patients with type 2 diabetes did not reduce A1C levels. The data of this study were obtained from a retrospective chart review and included a small number of subjects. Furthermore, large randomized controlled studies are needed to define the effect of PPIs for type 2 patients with diabetes.
    No preview · Article · Oct 2014 · Canadian Journal of Diabetes
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: The objective of this study was to evaluate the effects of voglibose on the pharmacokinetics of metformin. Methods: A randomized, open-label, two-way crossover study with a 7-day washout period was conducted. All subjects were given an oral dose of metformin with or without voglibose 3 x daily for 7 days. Plasma concentrations of metformin on day 7 were measured using high performance liquid chromatography (HPLC) with UV detection for pharmacokinetic assessment Vital signs and adverse events were monitored, and physical examinations and laboratory tests were conducted to evaluate safety. Results: 22 subjects completed the study. The geometric mean ratios for Css,max of metformin (metformin plus voglibose vs. metformin only) were 0.98 (90% CI, 0.92 - 1.05; p > 0.05) and for AUC-tau, the ratio was 0.99 (90% CI, 0.92 - 1.06; p > 0.05). There were no significant differences in adverse drug reactions between metformin with and without voglibose. However, the incidence of adverse events was higher in period 1 than in period 2 (16 cases vs. 1 case, p < 0.001). Conclusions: Co-administration of metformin and voglibose had no statistically or clinically significant effects on the pharmacokinetics of metformin in healthy subjects. The pharmacodynamic interaction study to evaluate the effect of metformin on the pharmacodynamics of voglibose is in progress.
    No preview · Article · Aug 2014 · International journal of clinical pharmacology and therapeutics
  • [Show abstract] [Hide abstract]
    ABSTRACT: We evaluated the effect of CYP2C19 genotype over time on the antiplatelet response of clopidogrel in healthy subjects. Seventy subjects for a pharmacodynamic study and twenty two subjects for a pharmacokinetic and pharmacodynamic study took 300 mg clopidogrel on the first day and 75 mg once daily for 6 consecutive days. The subjects with CYP2C19 poor metabolizer (PM, n = 22) and intermediate metabolizer (IM, n = 37) had significantly delayed time to inhibition of platelet aggregation (IPA) compared with CYP2C19 extensive metabolizer (EM, n = 33) (12 vs. 9 vs. 2 h as median Tmax , P < 0.05) after a 300 mg of clopidogrel. During maintenance dose of clopidogrel, IPA values of only CYP2C19 PM subjects were gradually decreased from 30.0 ± 21.9% on day 2 to 23.7 ± 16.6% on day 8 (P > 0.05 for time effect; P < 0.05 for time and genotype interaction effect). CYP2C19 PM had decreased Cmax and AUC of thiol metabolite compared with CYP2C19 EM (0.42 and 0.37 fold on day 1, P < 0.01; 0.39 and 0.34 fold on day 7, P < 0.01, respectively). Delayed time to reach maximal IPA as well as decreased IPA may influence the increased risk of the acute cardiac events in CYP2C19 PM and IM.
    No preview · Article · Aug 2014 · The Journal of Clinical Pharmacology
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to compare pharmacokinetic characteristics of fixed-dose combination (FDC) of two different salt form of amlodipine, amlodipine adipate/valsartan and amlodipine besylate/ valsartan, in healthy Korean volunteers under fasting conditions. A randomized, open-label, single-dose, two-treatment, two-way crossover study with a 14-day wash-out period was conducted. Plasma samples were collected for up to 144 hours for amlodipine and 24 hours for valsartan. Plasma concentrations of amlodipine and valsartan were analyzed using a validated ultra-performance liquid chromatography tandem mass-spectrometry. A non-compartmental method was used to calculate pharmacokinetic parameters. Vital signs and adverse events were monitored and physical examinations, laboratory tests, and electrocardiograms were conducted to evaluate safety. 44 subjects completed the study. The 90% CIs for the geometric mean ratio of Cmax and the AUC0-t were 93.5 - 100.4% and 93.2 - 98.3% for amlodipine, and 92.1 - 121.3% and 94.1 - 115.2% for valsartan, respectively. 17 adverse events occurred in 15 subjects during the study; 5 and 7 adverse drug reactions from the 5 and 6 subjects were considered to probably be related to the test and reference treatments respectively. All adverse drug reactions were in line with those known for the reference drug. All subjects recovered fully with no sequelae. A FDC of amlodipine adipate/valsartan and amlodipine besylate/ valsartan combination tablets met the regulatory criteria for bioequivalence. In addition, no significant difference was observed in the safety assessments between two treatments. Thus, the newly developed FDC of amlodipine adipate/valsartan seems to be interchangeable with amlodipine besylate valsartan combination.
    No preview · Article · Jul 2014 · International journal of clinical pharmacology and therapeutics
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Long-term data on lead complication rates are limited for both the axillary and subclavian venous approaches for permanent pacemaker implantation. Methods and results: We conducted a single-center, retrospective, nonrandomized comparison. We reviewed the patients who had consented to receiving a permanent pacemaker implant. A superficial landmark or radiographic contrast guiding was used for the axillary venous approach, whereas conventional landmarks were used for the subclavian venous approach. From January 1992 to December 2005, we analyzed 1,161 permanent pacemaker leads in 655 patients [subclavian venous approach (group I: 338 patients, 542 leads) and axillary venous approach (group II: 317 patients, 619 leads)]. Baseline characteristics of the patients did not differ. However, DDD-pacemakers and atrial leads were used more often in group II than in group I (94% vs. 62% and 49% vs. 40%, P<0.01). During the 8-year follow-up, lead complication rates were lower in group II (17 leads, 3%) than in group I (31 leads, 6%) (P=0.03), and group II had a better complication-free survival curve than group I with a 49% relative risk reduction in lead complication rates (hazard ratio =0.51; 95% confidence interval, 0.27-0.94; P=0.03). Conclusions: The axillary venous approach for permanent pacemaker implantation has better long-term efficacy and lower lead complication rates than the subclavian venous approach.
    No preview · Article · Mar 2014 · Circulation Journal
  • [Show abstract] [Hide abstract]
    ABSTRACT: The primary objective of this study was to evaluate the effects of Ginkgo biloba extracts (GBE) on the pharmacokinetics of cilostazol and its metabolites. Secondary objective was to assess the effect of GBE on pharmacodynamics of cilostazol. A randomized, double-blind, two-way crossover study was conducted with 34 healthy Korean subjects. All subjects were given an oral dose of cilostazol (100 mg) plus GBE (80 mg) or cilostazol (100 mg) plus placebo twice daily for 7 days. Plasma concentrations of cilostazol and its active metabolites (3,4-dehydrocilostazol and 4'-trans-hydroxycilostazol) were measured using liquid chromatography tandem mass spectroscopy (LC-MS/MS) on day 7 for pharmacokinetic assessment. ADP-induced platelet aggregation and bleeding time were measured at baseline and on day 7 for pharmacodynamic assessment. The geometric mean ratios of AUCτ for cilostazol plus GBE versus cilostazol plus placebo were 0.96 (90% CI, 0.89-1.03; p=0.20) for cilostazol; 0.96 (90% CI, 0.90-1.02; p=0.30) for 3,4-dehydrocilostazol; and 0.98 (90% CI, 0.93-1.03; p=0.47) for 4'-trans-hydroxycilostazol, respectively. The change of aggregation after administration of cilostazol plus GBE seemed to be 1.31 times higher compared with cilostazol plus placebo without statistical significance (p=0.20). There were no significant changes in bleeding time and adverse drug reaction between the treatments. Co-administration of GBE showed no statistically significant effects on the pharmacokinetics of cilostazol in healthy subjects. The long-term large cohort clinical study seems to be remained to evaluate the possible pharmacodynamic interaction between cilostazol and GBE, since there was remarkable, but no statistically significant, increase of platelet aggregation inhibition.
    No preview · Article · Sep 2013 · British Journal of Clinical Pharmacology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Leflunomide is a disease-modifying antirheumatic drug. The purpose of this study was to evaluate the bioequivalence of a test drug (CJ leflunomide) and a commercially available reference drug (Arava®) at 2 doses (10 and 20 mg) in healthy Korean volunteers. This was a single-dose (28 individuals enrolled at each dose group), randomized, open-label, 2-way crossover study. The 2 treatment periods were separated by a 56-day wash-out interval. Blood sampling was conducted until 672 h after drug administration. Plasma teriflunomide (active metabolite of leflunomide) concentrations were determined, and pharmacokinetic parameters were calculated. Bioequivalence was evaluated using an ANOVA model, based on the AUCt and the Cmax after administration of leflunomide tablets. Bioequivalence was defined as the 90% confidence intervals (CIs) of the geometric mean ratios (GMRs) of AUCt and Cmax for the test and reference drugs being within the range of 0.80-1.25. The GMRs (90% CI) for AUCt and Cmax were 0.9506 (0.9091-0.9941) and 0.9861 (0.9360-1.0389), respectively, in the 10 mg study, and 0.9524 (0.9101-0.9968) and 0.9740 (0.9314-1.0186), respectively, in the 20 mg study. The 90% CIs of AUCt and Cmax at each dose were within the accepted range for bioequivalence. Based on the results, the test drug (CJ leflunomide) was bioequivalent to the commercially available reference drug (Arava®) at both doses.
    No preview · Article · Jul 2013

  • No preview · Article · Jun 2013
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Fentanyl, a μ-opioid receptor agonist, is a substrate of P-glycoprotein. Its metabolism is catalyzed by CYP3A4 and CYP3A5. The aim of this study was to investigate the association between postoperative fentanyl consumption and genetic polymorphisms of μ-opioid receptor (OPRM1), ABCB1 (gene encoding P-glycoprotein), CYP3A4 and CYP3A5 in Korean patients. Methods: 196 female patients scheduled to undergo total abdominal hysterectomy or laparoscopic assisted vaginal hysterectomy under general anesthesia were enrolled in this study. Intravenous patient-controlled analgesia with fentanyl was provided postoperatively. Cumulative fentanyl consumption was measured during the first 48 hours postoperatively. The severity of pain at rest was assessed with the visual analogue scale. OPRM1 118A>G, ABCB1 2677G>A/T, ABCB1 3435C>T, CYP3A4*18 and CYP3A5*3 variant alleles were genotyped. The effects of genetic and non-genetic factors on fentanyl requirements were evaluated with multiple linear regression analysis. Results: The 24-hour cumulative fentanyl doses were significantly associated with pain core, weight and type of surgery (p < 0.05). The 48-hour cumulative fentanyl doses were significantly associated with pain score, type of surgery and history of PONV or motion sickness (p < 0.05). Genetic polymorphisms were not associated with fentanyl requirements. Conclusion: In Korean gynecologic patients, no association was found between genetic factors and postoperative fentanyl consumption.
    No preview · Article · Apr 2013 · International journal of clinical pharmacology and therapeutics
  • Source

    Full-text · Article · Mar 2013 · Journal of the American College of Cardiology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To evaluate retrospectively whether symptomatic acromioclavicular joints can be differentiated from asymptomatic acromioclavicular joints on 3-T MR imaging. Methods: This study included 146 patients who underwent physical examination of acromioclavicular joints and 3-T MR imaging of the shoulder. Among them, 67 patients showing positive results on physical examination were assigned to the symptomatic group, whereas 79 showing negative results were assigned to the asymptomatic group. The following MR findings were compared between the symptomatic and asymptomatic groups: presence of osteophytes, articular surface irregularity, subchondral cysts, acromioclavicular joint fluid, subacromial fluid, subacromial bony spurs, joint capsular distension, bone edema, intraarticular enhancement, periarticular enhancement, superior and inferior joint capsular distension degree, and joint capsular thickness. The patients were subsequently divided into groups based on age (younger, older) and the method of MR arthrography (direct MR arthrography, indirect MR arthrography), and all the MR findings in each subgroup were reanalyzed. The meaningful cutoff value of each significant continuous variable was calculated using receiver operating characteristic analysis. Results: The degree of superior capsular distension was the only significant MR finding of symptomatic acromioclavicular joints and its meaningful cutoff value was 2.1mm. After subgroup analyses, this variable was significant in the older age group and indirect MR arthrography group. Conclusion: On 3-T MR imaging, the degree of superior joint capsular distension might be a predictable MR finding in the diagnosis of symptomatic acromioclavicular joints.
    No preview · Article · Dec 2012 · European journal of radiology
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to analyze the oncologic outcomes and the risk factors for recurrence after a tumor-specific mesorectal excision (TSME) of resectable rectal cancer in a single institution. A total of 782 patients who underwent a TSME for resectable rectal cancer between February 1995 and December 2005 were enrolled retrospectively. Oncologic outcomes included 5-year cancer-specific survival and its affecting factors, as well as risk factors for local and systemic recurrence. The 5-year cancer-specific survival rate was 77.53% with a mean follow-up period of 61 ± 31 months. The overall local and systemic recurrence rates were 9.2% and 21.1%, respectively. The risk factors for local recurrence were pN stage (P = 0.015), positive distal resection margin, and positive circumferential resection margin (P < 0.001). The risk factors for systemic recurrence were pN stage (P < 0.001) and preoperative carcinoembryonic antigen level (P = 0.005). The prognostic factors for cancer-specific survival were pT stage (P < 0.001), pN stage (P < 0.001), positive distal resection margin (P = 0.005), and positive circumferential resection margin (P = 0.016). The oncologic outcomes in our institution after a TSME for patients with resectable rectal cancer were similar to those reported in other recent studies, and we established the risk factors that could be crucial for the planning of treatment and follow-up.
    Full-text · Article · Apr 2012 · Journal of the Korean Society of Coloproctology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Parkinson’s disease (PD) can be divided into the akinetic-rigid (ART), mixed (MT), and tremor-dominant (TDT) subtypes according to the clinically dominant symptoms. We analyzed the correlations between 123I-meta-iodobenzylguanidine (MIBG) uptake and the clinical features of patients with various PD subtypes. In addition, we evaluated the relationship between MIBG uptake and the severity of the cardinal motor symptoms among patients with PD subtypes. The mean Unified Parkinson’s Disease Rating Scale motor scores differed significantly among patients with different PD subtypes (± standard deviation [SD]) (ART, 34.6±18.28; MT, 24.63±7.78; TDT, 16.22±4.15, p=0.002), especially between the ART and TDT subtypes (p=0.022). The mean MIBG uptake (± SD) was decreased in the TDT (1.69±0.39), MT (1.35±0.32), and ART (1.35±0.22) subtypes (p=0.049). The MIBG uptake values differed significantly between the ART and TDT subtypes (p=0.02). The MIBG uptake was inversely correlated with the severity of hypokinesia in the ART subtype (r=−0.75; p=0.01) and the MT subtype (r=−0.8; p=0.02), but it was not correlated with the severity of any of the parkinsonian motor symptoms in the TDT subtype. These results imply that hypokinesia is strongly associated with sympathetic myocardial degeneration and that sympathetic myocardial degeneration can reflect the progression of the disease in patients with the ART and mixed MT subtypes of PD.
    No preview · Article · Jul 2011 · Journal of Clinical Neuroscience
  • [Show abstract] [Hide abstract]
    ABSTRACT: To associate the global gene expression of B7/CD28 family transcripts with pathologic features of colon cancer, we determined the B7/CD28 family transcripts in peripheral blood mononuclear cells (PBMCs) from normal subjects and patients with adenomatous polyps and colon cancer, and correlated the results with pathologic features of colon cancer. PBMCs from age-matched normal subjects and patients with adenomatous polyps and colon cancer were analyzed for peripheral blood transcripts (PBTs) of B7/CD28 family using real-time PCR. Differences in expression levels of B7/CD28 PBTs across all cancer stages and between colon cancer patients with or without microscopic lymphovascular invasion (LVI) were analyzed. The results showed a significant upregulation of PBTs of co-inhibitory molecules such as B7-H3 and PD-1 and a significant PBT downregulation of co-stimulatory molecules including CD28 and ICOS in colon cancer patients. Furthermore, the increase of B7-H3 PBT was strongly associated with tumor invasion (P = 0.025) and advanced TNM stages (P = 0.019), whereas the decline of co-stimulatory ligand B7-H2 PBT was related to regional lymph node metastasis (P = 0.028) and aggressive tumor invasion (P = 0.031). In addition, the ratios of PBT expression of CD28 family to B7 family such as CTLA-4 to B7-H2 and PD-1 to B7-H2 were significantly higher in colon cancer patients with microscopic LVI than in those without LVI (P = 0.001 and P = 0.016, respectively). Our results suggest that B7/CD28 family PBTs may serve as valuable markers reflecting the pathological features of colon cancer.
    No preview · Article · Feb 2010 · Journal of Cancer Research and Clinical Oncology
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background and Purpose: Several studies have reported that diffusion-weighted imaging (DWI) is able to help discriminate a Parkinson variant of multiple system atrophy (MSA-p) from Parkinson’s disease (PD) on the basis of the increased regional apparent diffusion coefficient (rADC). We analyzed the usefulness of DWI by using the rADC for differential diagnosis between MSA-p and PD and investigated the correlation between the rADC value and clinical features of MSA-p and PD. Methods: Twelve patients with PD and 10 with MSA-p were studied. The rADC value was determined in different brain regions, including the dorsal putamen (DP) and middle cerebellar peduncles (MCP). Results: The rADC values of the DP showed a greater increase in MSA-p patients than in PD patients (p=0.03). MSA-p patients also presented increased rADC values of the MCP compared with PD patients (p=0.0001). In particular, the sensitivity, specificity and positive predictive values of the MCP rADC were higher than those of the DP rADC. However, DP and MCP rADC values were not correlated with clinical features in either MSA or PD patients. Conclusions: DWI discriminated between PD and MSA-p based on rADC values in DP and MCP. The MCP rADC value, in particular, could better discriminate MSA-p from PD.
    Full-text · Article · Oct 2009

Publication Stats

131 Citations
57.53 Total Impact Points


  • 2010-2015
    • Inje University Paik Hospital
      • Department of Internal Medicine
      Sŏul, Seoul, South Korea
  • 2008-2015
    • Inje University
      • • PharmacoGenomics Research Center
      • • College of Medicine
      Kŭmhae, Gyeongsangnam-do, South Korea